Compare with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES DR. REDDYS LAB ALKEM LABORATORIES/
DR. REDDYS LAB
 
P/E (TTM) x 22.4 34.8 64.2% View Chart
P/BV x 5.4 4.8 113.2% View Chart
Dividend Yield % 0.9 0.6 161.4%  

Financials

 ALKEM LABORATORIES   DR. REDDYS LAB
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
DR. REDDYS LAB
Mar-20
ALKEM LABORATORIES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs2,7203,363 80.9%   
Low Rs1,6602,352 70.6%   
Sales per share (Unadj.) Rs697.91,054.2 66.2%  
Earnings per share (Unadj.) Rs96.1121.9 78.8%  
Cash flow per share (Unadj.) Rs117.3190.2 61.6%  
Dividends per share (Unadj.) Rs25.0025.00 100.0%  
Dividend yield (eoy) %1.10.9 130.5%  
Book value per share (Unadj.) Rs515.2938.7 54.9%  
Shares outstanding (eoy) m119.57166.17 72.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.7 115.8%   
Avg P/E ratio x22.823.4 97.2%  
P/CF ratio (eoy) x18.715.0 124.3%  
Price / Book Value ratio x4.33.0 139.6%  
Dividend payout %26.020.5 126.8%   
Avg Mkt Cap Rs m261,879474,831 55.2%   
No. of employees `00014.321.7 66.2%   
Total wages/salary Rs m15,05533,802 44.5%   
Avg. sales/employee Rs Th5,822.68,091.0 72.0%   
Avg. wages/employee Rs Th1,050.51,561.3 67.3%   
Avg. net profit/employee Rs Th802.0935.8 85.7%   
INCOME DATA
Net Sales Rs m83,444175,170 47.6%  
Other income Rs m1,0426,206 16.8%   
Total revenues Rs m84,486181,376 46.6%   
Gross profit Rs m14,73424,421 60.3%  
Depreciation Rs m2,52811,348 22.3%   
Interest Rs m651983 66.2%   
Profit before tax Rs m12,59818,296 68.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,105-1,403 -78.7%   
Profit after tax Rs m11,49320,260 56.7%  
Gross profit margin %17.713.9 126.7%  
Effective tax rate %8.8-7.7 -114.4%   
Net profit margin %13.811.6 119.1%  
BALANCE SHEET DATA
Current assets Rs m54,960125,991 43.6%   
Current liabilities Rs m32,43372,141 45.0%   
Net working cap to sales %27.030.7 87.8%  
Current ratio x1.71.7 97.0%  
Inventory Days Days8073 108.9%  
Debtors Days Days72105 68.9%  
Net fixed assets Rs m32,71083,854 39.0%   
Share capital Rs m239831 28.8%   
"Free" reserves Rs m61,368155,157 39.6%   
Net worth Rs m61,607155,988 39.5%   
Long term debt Rs m1,5921,304 122.1%   
Total assets Rs m99,433232,253 42.8%  
Interest coverage x20.419.6 103.8%   
Debt to equity ratio x00 309.2%  
Sales to assets ratio x0.80.8 111.3%   
Return on assets %12.29.1 133.5%  
Return on equity %18.713.0 143.6%  
Return on capital %21.012.6 166.2%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06184,193 19.1%   
Fx outflow Rs m2,48339,616 6.3%   
Net fx Rs m13,57844,577 30.5%   
CASH FLOW
From Operations Rs m5,85129,841 19.6%  
From Investments Rs m-7,414-4,923 150.6%  
From Financial Activity Rs m792-25,159 -3.1%  
Net Cashflow Rs m-731-266 274.8%  

Share Holding

Indian Promoters % 66.9 25.5 262.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.4 613.0%  
FIIs % 0.0 35.3 -  
ADR/GDR % 0.0 18.5 -  
Free float % 0.0 15.3 -  
Shareholders   68,381 75,885 90.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   SUN PHARMA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  CIPLA  GSK PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS